Figure 8From: Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinomaSurvival analysis of prognostic factors of patients with FLC. Patients with (n = 10, median survival of 26 ± 11 months) and without (n = 5, median survival of 65 ± 21 months) altered liver enzymes, p = 0.04.Back to article page